Specialist valuations for Australian community pharmacies and their PBS approvals.

A pharmacy valuation determines the market value of a community pharmacy business, where goodwill attaches to the PBS approval number because location rules and pharmacist-only ownership restrict supply. Prismi prepares evidence-led pharmacy valuations for sales, partnership changes, related-party transfers, CGT concession claims and restructures, cross-checking capitalised earnings against dollars-per-script and percentage-of-turnover benchmarks and concluding at the most supportable position.

When a pharmacy needs a formal valuation

Pharmacy valuations are commissioned around ownership events: sale or purchase of the pharmacy business, admission or exit of a partner, transfer of an interest to a family trust or related entity, or a restructure of the holding arrangements. Because state ownership caps push most groups into multi-partner structures, partnership changes are the single most common trigger — every admission and exit needs a number both sides and their advisers can rely on. Related-party transfers engage the market value substitution rule in s 116-30 ITAA 1997, exits engage the Division 152 small business CGT concessions, and restructures may rely on the Subdivision 328-G rollover — all positions that need a market valuation prepared with ATO market valuation expectations in mind. Lenders also require valuations at purchase and refinance. Prismi's fees are fixed at engagement and never contingent on the outcome, and every report is senior-reviewer signed with a formal independence statement.

Why goodwill attaches to the PBS approval number

The right to dispense PBS medicines at a location is an approval granted under the National Health Act 1953. New pharmacies and relocations are assessed by the Australian Community Pharmacy Authority against the pharmacy location rules — a legislative instrument that tightly restricts where a new approval can be established, and which is no longer subject to a sunset date. On the ownership side, every state and territory except the Northern Territory restricts pharmacy ownership to registered pharmacists, with limited friendly society exceptions, and most impose numerical caps: four concurrent pharmacies in Western Australia and Tasmania, five in New South Wales and Victoria, six in South Australia, and no cap in the ACT or NT. Queensland has moved to a licensing regime under the Pharmacy Business Ownership Act 2024, administered by the new Queensland Pharmacy Business Ownership Council. The combined effect is a supply-constrained licence market: goodwill attaches to the approval number itself, not merely to the trading performance behind it, and pharmacies routinely transact at prices a pure earnings analysis would struggle to reproduce. A supportable pharmacy valuation names that scarcity premium and evidences it, rather than burying it in the multiple.

Dispensing remuneration and the 60-day shift

Dispensary income per script is built from regulated components: the flat dispensing fee, the tiered Administration, Handling and Infrastructure (AHI) fee that scales with the price of the medicine, and applicable markups — with the dispensing fee and Tier 1 AHI indexed each 1 July under the Eighth Community Pharmacy Agreement that commenced on 1 July 2024. Sixty-day dispensing, phased in from 1 September 2023 across three tranches to more than 300 eligible medicines by September 2024, collapses two dispensing events into one on affected molecules — a direct hit to script-count economics that the Additional Community Supply Support payments (an AHI-equivalent fee on eligible 60-day scripts plus a balancing fee on above-co-payment scripts) only partly restore. The reduction of the general PBS co-payment from $31.60 to $25 on 1 January 2026 further shifts which scripts sit above or below the co-payment and how discounting behaves. The valuation consequence is blunt: maintainable earnings cannot be read off a prior-year profit and loss. They have to be rebuilt from dispense-system data — script volumes, 60-day penetration by molecule, and remuneration per script under current settings.

Dispensary versus front of shop: margin quality matters

Two pharmacies with identical turnover can deserve materially different multiples. Dispensary revenue is high-certainty but regulated: successive price disclosure cycles have compressed gross margin on high-volume generics, and remuneration is set by instrument rather than by the owner. Front-of-shop revenue carries nominally higher margins but competes with discounters, supermarkets and online channels, and is far more sensitive to location and retail skill. Professional services revenue — vaccinations, medication reviews and expanding scope-of-practice programs — is growing and attracts separate program funding, but is also practitioner-dependent. The working file records the revenue and gross margin split across these streams because the split is a primary driver of where in the supportable range the conclusion should sit: a dispensary-led pharmacy with strong generic substitution and a lean front of shop is a different risk asset from a retail-led pharmacy with the same EBITDA.

$/script, percentage of turnover and why bank lending props up multiples

Capitalisation of maintainable EBITDA is the primary methodology, with proprietor pharmacist remuneration normalised to market for the hours actually worked. The result is then cross-checked against the two metrics the pharmacy market actually trades on: dollars per annual dispensed script and price as a percentage of turnover. Where the capitalised earnings result implies a $/script figure outside what the market is observably paying, the report reconciles the gap rather than ignoring it — often the explanation is the scarcity premium on the approval, or debt availability. Community Service Obligation arrangements oblige funded wholesalers to supply the full PBS range to any community pharmacy within defined service standards, which underpins stock availability and trading terms, and banks treat PBS-derived income as annuity-like — lending against pharmacy goodwill at loan-to-value ratios few other business classes attract. That debt availability supports transaction prices relative to underlying earnings risk. An evidence-led report says so explicitly, because a multiple propped up by lender appetite is a different supportable position from one earned by the business itself.

What the valuation file needs from a pharmacy

• ·Dispense-system reports: monthly script volumes, 60-day script share, and dispensary sales by PBS, private and OTC category, ideally three years
• ·PBS approval number details and any ACPA correspondence on establishment or relocation
• ·Financial statements and tax returns for the trading entity and any partnership or service entities (three to five years)
• ·Wholesaler statements and trading terms, including CSO wholesaler arrangements and rebate structures
• ·Premises lease, including tenure, options and any shopping-centre turnover rent clauses
• ·Award wage rosters and proprietor working hours, for pharmacist remuneration normalisation
• ·Partnership or shareholders agreement, including pre-emptive rights and any valuation clauses

Which Prismi tier fits a pharmacy valuation

Most pharmacy engagements are Comprehensive (from $3,995 + GST, 15–25 business days): partnership admissions and exits, related-party transfers and pre-sale positions where the parties need a reasoned report with full methodology. The Defensible Valuation File (from $8,995 + GST, 25–35 business days) is the right tier where the number is likely to be tested — higher-value pharmacies, contested partnership exits, and CGT positions that may face ATO review — because it documents the script-volume analysis, cross-checks and scarcity-premium reasoning at working-paper depth, with the working file retained for ten years. Essential (from $1,495 + GST, 10–14 business days) suits indicative internal planning only; the remuneration mechanics above generally justify the deeper tiers. Where partners disagree on value or a 60-day-exposed dispensary needs scenario testing, the Valuation Range & Scenario Review premium engagement models the alternatives explicitly. Retrospective valuations at historical dates attract a $495 surcharge per date, additional entities are $750 each — common where partnership, trading and service entities all hold interests — and rush delivery is +30% of the base fee, subject to capacity. If a client needs a particular number rather than a supportable one, we will say so and decline the engagement on those terms.